Company
Impedimed
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
4
As lead sponsor, any status
Adverse event reports
1
Received Nov 1, 2025 to Nov 20, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Impedimed, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Impedimed.
Latest FDA decisions
The 8 newest of 11 since 2015.
K260224 · Decided Aug 17, 2026 · 203 days after receipt
Device type: Plethysmograph, Impedance (DSB) · Cardiology
K253224 · Decided Jan 28, 2026 · 121 days after receipt
Device type: Monitor, Extracellular Fluid, Lymphedema, Extremity (OBH) · Cardiology
- SOZO Pro510(k)
K232089 · Decided Oct 17, 2023 · 96 days after receipt
Device type: Plethysmograph, Impedance (DSB) · Cardiology
8 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Observational Study of BIS in Hemodialysis PatientsStatus unknown
NCT05381961 · 70 participants (planned) · Start Apr 4, 2022 · Primary completion Nov 8, 2022
Device: Bioimpedance spectroscopy (BIS) measurement, SOZO device · For: Kidney Failure, Chronic; Renal Failure Chronic; Hemodialysis
Sites: San Diego, California · 2 sites in all
NCT04013373 · 92 participants · Start Oct 9, 2018 · Primary completion Jul 30, 2020
Device: SOZO Bioimpedance Spectroscopy Device · For: Heart Failure
Sites: Canoga Park, California; Encinitas, California; Garden Grove, California · 15 sites in all
- Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)Pivotal-lookingCompleted
NCT02167659 · 1,201 participants · Start Jun 2014 · Primary completion Dec 31, 2020
Device: 23-32 mmHg compression sleeve with gauntlet · For: Lymphedema
Sites: Jacksonville, Florida; Kansas City, Kansas; Louisville, Kentucky · 10 sites in all
1 more trials with a free account
Reports received
1
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- SOZO Bilateral Arm L-Dex SoftwareOpen, Classified
Z-0155-2024 · Started Aug 17, 2023 · Posted by FDA Oct 24, 2023
Reason given: Bilateral L-Dex assessment software does not have the same level of sensitivity to help detect early signs of lymphedema as the unilateral arm L-Dex assessment, which could result in under-recognition of early lymphedema, which could result in delay in early intervention, and more aggressive intervention.
Cause as FDA categorized it: Device Design · Device type: Monitor, Extracellular Fluid, Lymphedema, Extremity (OBH)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.